Brainstorm Cell Therapeutics Inc. announced that On December 17, 2023, the Board appointed Dr. Menghisteab Bairu to the Audit Committee of the Board to replace Dr. June S. Almenoff, effective from December 18, 2023. The Board has determined that Dr. Menghisteab Bairu meets the requirements for independence of Audit Committee members under the applicable listing standards of Nasdaq and the Securities Exchange Act of 1934, as amended. Effective as of December 18, 2023, the Audit Committee is composed of Mr. Nir Naor (Chair), Dr. Irit Arbel and Dr. Menghisteab Bairu.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5345 USD | +0.47% | +0.47% | +95.79% |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.79% | 36.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- Brainstorm Cell Therapeutics Inc. Announces Executive Changes